Dr Nadia Mazarakis
Dr Nadia Mazarakis
Details
Role
Research Officer
Research area
Infection, Immunity and Global Health
Group
Vaccine Immunology
Dr Nadia Mazarakis is a research officer in the Vaccine Immunology group under A/Prof Paul Licciardi at Murdoch Children’s Research Institute (MCRI). Her current research focuses on evaluating the immunogenicity of COVID-19 vaccines as a booster dose in a global randomised controlled trial, funded by the Coalition for Epidemic Preparedness Innovations (CEPI). Nadia also has an honorary appointment with the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Department of Paediatrics.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
Dr Nadia Mazarakis is a research officer in the Vaccine Immunology group under A/Prof Paul Licciardi at Murdoch Children’s Research Institute (MCRI). Her current research focuses on evaluating the immunogenicity of COVID-19 vaccines as a booster...
Dr Nadia Mazarakis is a research officer in the Vaccine Immunology group under A/Prof Paul Licciardi at Murdoch Children’s Research Institute (MCRI). Her current research focuses on evaluating the immunogenicity of COVID-19 vaccines as a booster dose in a global randomised controlled trial, funded by the Coalition for Epidemic Preparedness Innovations (CEPI). Nadia also has an honorary appointment with the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences, Department of Paediatrics.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
She completed her PhD at the University of Melbourne in 2021. Her PhD thesis evaluated the critical biological health-benefiting properties of the dietary compound L-sulforaphane (LSF) in relevant models of inflammatory disease. Prior to her PhD, she completed a Masters of Bioethics at Monash University.
Top Publications
- Moscatelli, OG, Russell, AK, Henneken, LM, Hardy, MY, Mazarakis, N, Higgins, R, Ekin, J, McLeod, H, Simkin, P, Licciardi, PV, et al. Impaired IgM Memory B Cell Function Is Common in Coeliac Disease but Conjugate Pneumococcal Vaccination Induces Robust Protective Immunity.. Vaccines (Basel) 12(2) : 2024 view publication
- Toh, ZQ, Anderson, J, Mazarakis, N, Neeland, M, Higgins, RA, Rautenbacher, K, Dohle, K, Nguyen, J, Overmars, I, Donato, C, et al. Reduced seroconversion in children compared to adults with mild COVID-19. 2024 view publication
- Royce, S, Licciardi, P, Beh, R, Bourke, J, Cooper, M, Donovan, C, Hung, A, Khurana, I, Liang, J, Maxwell, S, et al. Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant and epigenetic mechanisms. 2024 view publication
- Toh, ZQ, Mazarakis, N, Nguyen, J, Higgins, RA, Anderson, J, Ha, LA, Burgner, DP, Curtis, N, Steer, AC, Mulholland, K, et al. Comparison of antibody responses to SARS-CoV-2 variants in Australian children. 2024 view publication
- Batmunkh, T, Moore, KA, Thomson, H, Altangerel, B, Amraa, O, Avaa, N, Batbayar, L, Batsukh, K, Bright, K, Burentogtokh, T, et al. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.. Lancet Reg Health West Pac 42: 100953 2024 view publication
Page 1 of 4
Share //
